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Abstract
Our aim is to summarize and discuss the recent literature linking diabetes mellitus with heart
failure, and to address the issue of the optimal treatment for diabetic patients with heart failure.
The studies linking diabetes mellitus (DM) with heart failure (HF): The prevalence of
diabetes mellitus in heart failure populations is close to 20% compared with 4 to 6% in control
populations. Epidemiological studies have demonstrated an increased risk of heart failure in
diabetics; moreover, in diabetic populations, poor glycemic control has been associated with an
increased risk of heart failure. Various mechanisms may link diabetes mellitus to heart failure: firstly,
associated comorbidities such as hypertension may play a role; secondly, diabetes accelerates the
development of coronary atherosclerosis; thirdly, experimental and clinical studies support the
existence of a specific diabetic cardiomyopathy related to microangiopathy, metabolic factors or
myocardial fibrosis. Subgroup analyses of randomized trials demonstrate that diabetes is also an
important prognostic factor in heart failure. In addition, it has been suggested that the deleterious
impact of diabetes may be especially marked in patients with ischemic cardiomyopathy.
Treatment of heart failure in diabetic patients: The knowledge of the diabetic status may
help to define the optimal therapeutic strategy for heart failure patients. Cornerstone treatments
such as ACE inhibitors or beta-blockers appear to be uniformly beneficial in diabetic and non
diabetic populations. However, in ischemic cardiomyopathy, the choice of the revascularization
technique may differ according to diabetic status. Finally, clinical studies are needed to determine
whether improved metabolic control might favorably influence the outcome of diabetic heart
failure patients.
Background
Heart failure (HF) is a major and growing public health is-
sue. It is estimated that approximately 4 to 5 million
Americans have HF, and that an additional 400,000 pa-
tients are diagnosed with HF each year [1]. HF prevalence
is expected to reach 10 million cases in the U.S. by the year
2007 [2].
In spite of significant advances in management and treat-
ment, the mortality of patients with HF remains high. In
the CIBIS II (Cardiac Insufficiency Bisoprolol Study II) tri-
al, after a median follow-up of 15 months, the all cause
mortality was 11.8% in the group of patients receiving the
beta-blocker bisoprolol [3]. In the ATLAS (Assessment of
Treatment with Lisinopril And Survival) trial, after a me-
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dian follow-up of 46 months, the all cause mortality was
42% in the group of patients randomized to high dose of
the angiotensin converting enzyme (ACE) inhibitor lisi-
nopril [4]. In unselected populations, the outcome is even
worse. Data from the Medicare population demonstrated
a 6-year mortality rate in HF patients of 84% in men and
77% in women [5]. In the EPICAL (Epidémiologie de l'In-
suffisance Cardiaque Avancée en Lorraine) observational
study, the all cause one-year mortality was 35.4% [6].
HF is also a major cause of morbidity; chronic HF results
in almost 1 million hospitalizations each year in the U.S.
[7]. This has a major impact on health care expenditure.
In 1991, the total inpatient and outpatient costs for HF
were estimated to be $38 billion (5.4% of the health care
budget that year) [8]. As the population ages and the
number of patients with HF increases, the economic bur-
den of HF will inevitably increase [9].
Over recent years, the prevalence of diabetes mellitus
(DM), in particular type II diabetes, has increased signifi-
cantly. The prevalence of DM in adults worldwide was es-
timated to be 4% in 1995 and is projected to rise to 5.4%
by the year 2025 [10]. In developed countries, the preva-
lence of DM is higher in the elderly (over 65 years) popu-
lation [11] (Figure 1). DM is a well known and important
risk factor for cardiac disease [12–15].
Figure 1
Prevalence of diabetes mellitus in an unselected population. This figure shows the prevalence of diabetes mellitus 
stratified by sex and age in the Framingham cohort. A higher proportion of diabetics is observed in subjects aged over 65 years. 
Adapted from reference [11].
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While the most common cardiac manifestation in diabet-
ic patients is coronary artery disease, DM also appears to
be strongly linked to HF. Approximately 15 to 25% of pa-
tients with HF are diabetics [6,16–18] and it has been sug-
gested that DM may play an important role in the
pathogenesis, prognosis, and response to treatment of HF
[19]. In addition, advanced HF is related to marked insu-
lin resistance [20]. The aim of this paper will be to sum-
marize and discuss the available literature linking DM
with HF, and to address the issue of the optimal treatment
for diabetic patients with HF.
The studies linking DM with HF
The epidemiological evidence linking DM with HF
As shown by subgroup analyses of randomized studies, a
significant proportion of patients with HF are diabetics
(Figure 2). In the SOLVD (Studies of Left Ventricular Dys-
function) clinical trials, 15% of patients were diabetic in
the Prevention arm and 26% in the Treatment arm [17].
In the V-HeFT II (Vasodilator Heart Failure Trial II), the
proportion of patients with DM was 20% [16]. More re-
cently, Ryden et al reported the results of the ATLAS study
in patients with and without DM: of the 3164 patients in-
cluded in the study, 611 (19%) were taking hypoglycemic
agents (oral or insulin) at baseline and were considered as
having clinical DM [18]. Information on the prevalence of
DM in HF populations can also be obtained from regis-
tries; the unselected nature of the patients consecutively
included in registries may provide a better estimate of the
true rate of DM in patients with HF. The SOLVD Registry
was conducted in conjunction with the Prevention and
the Treatment trials and enrolled a large cohort of patients
with an ejection fraction <45% to determine the baseline
characteristics of a population with left ventricular dys-
Figure 2
Prevalence of diabetes mellitus in HF populations according to HF etiology. This figure shows the prevalence of dia-
betes mellitus in 3 different populations [6,18,27]. A high proportion of diabetics was observed in all 3 studies.
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Figure 3
Incidence of HF and coronary artery disease (CAD) as a function of diabetes mellitus in general populations. 
The rates of both HF (Fig 3A) and CAD (Fig 3B) are higher in diabetics. The relative risks are higher for women than for men. 
Adapted from reference [11].
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function. A total of 6076 patients with left ventricular dys-
function were included in the SOLVD Registry; among
these, 1425 (23%) were classified as diabetics by the in-
vestigators [17]. In the EPICAL study [6], a registry of con-
secutive patients hospitalized for advanced chronic HF
due to left ventricular systolic dysfunction (ejection frac-
tion <30%), 26% of patients had an history of type I or
type II DM. Overall, the rate of DM in HF populations is
thus close to 20%. This rate is much higher than the 4 to
6% prevalence of DM observed in age-matched control
populations [10,11] (Figure 1).
The first demonstration of an increased risk of HF in pa-
tients with DM was reported by Kannel and McGee [11]
based on data obtained from 20 years follow-up of the
Framingham cohort. The incidence of HF according to sex
and diabetic status is shown in Figure 3A; an increased risk
of HF was observed in patients with DM. Compared with
non-diabetic males and females, the age-adjusted relative
risks of HF for diabetic males and females were 2.20 and
5.37, respectively [11]. In a study by Tenenbaum et al in
patients with ischemic heart disease, the incidence of HF
at 6 to 9-year follow-up was 35.7% in non diabetic pa-
tients, 39% in patients with impaired fasting glucose and
45.7% in diabetic patients [21]. Other studies have dem-
onstrated that the incidence of HF in diabetic patients is
significantly correlated with HbA1c levels. This was pri-
marily shown in the UK Prospective Diabetes Study
(UKPDS) [22] (Figure 4A). These results were confirmed
in a large population-based sample of 48,858 diabetic pa-
tients [23]; after adjustment for age and sex, each 1% in-
crease in HbA1c was associated with a 12% increased risk
of hospitalization for HF and/or death. These data dem-
onstrating a strong association between HbA1c levels and
HF in diabetic populations should be interpretated with
caution; although poor glycemic control may be an inde-
pendent risk factor for developing HF in diabetic popula-
tions, it is also conceivable that these data simply suggest
a longer duration of DM, which is difficult to control, and
therefore the development of HF may be more closely re-
lated to the duration of DM than to glycemic control.
Finally, although our aim was to review studies analyzing
the risk of HF as a function of diabetic status, it must also
be acknowledged that HF may predict future DM develop-
ment; this has been demonstrated in an elderly popula-
tion by Amato et al [24].
The mechanisms of HF in diabetic patients
DM may be causally related to HF development by at least
3 mechanisms: due to associated comorbidities, by favor-
ing the development of coronary atherosclerosis, or
through a specific diabetic cardiomyopathy.
Associated comorbidities or risk factors may partly ac-
count for the increased risk of HF in diabetic patients.
These cardiovascular risk factors such as dyslipidaemia,
hypertension, hypercoagulability, obesity and inflamma-
tion are part of the insulin resistance syndrome and are, at
least partly, regulated by nuclear peroxisome proliferator-
activated receptors (PPARs); activation of PPAR-gamma
improve insulin sensitivity and endothelial function, and
lower inflammation and blood pressure [25]. In the Fram-
ingham cohort, diabetic men and women had higher
blood pressures and were more obese than non-diabetics;
diabetic women had, in addition, higher LDL-cholesterol
values; HDL-cholesterol values were consistently lower in
those with DM than in those without DM in both sexes
[26]. The same observation has been reported in HF pop-
ulations: In the SOLVD trials [17,27], for example, diabet-
ic patients were older and were more likely to have a
history of hypertension than non-diabetic patients: in the
treatment arm, 54% of diabetics had hypertension versus
38% of non-diabetics (p < 0.001); in the prevention arm,
53% of diabetics had hypertension versus 34% of non-di-
abetics (p < 0.001). Although this may in part explain the
higher incidence of HF in diabetic patients, other mecha-
nisms must also play a role. Indeed, in most of the studies
discussed previously, diabetes or poor glycemic control re-
mained significantly associated with HF after adjustment
for important baseline clinical variables including age,
sex, and hypertension [11,22,23].
The increased risk of atherosclerosis in diabetic patients
may also contribute significantly to the increased risk of
HF. Coronary artery disease is the underlying cause of HF
in approximately two thirds of patients with left ventricu-
lar systolic dysfunction [28]. DM is associated with a
markedly increased risk of coronary artery disease. In the
Framingham study, the incidence of coronary artery dis-
ease was increased in diabetic subjects (Figure 3B). In
UKPDS, the risk of myocardial infarction increased as a
function of HbA1c levels [22] (Figure 4B). In the study by
Haffner et al [29], the seven-year incidence rate of myocar-
dial infarction in diabetic subjects without prior myocar-
dial infarction at baseline was 20.2% versus only 3.5% in
non-diabetic subjects without prior myocardial infarction
at baseline (Figure 5). This increased risk of atherosclero-
sis in diabetic subjects has been attributed to diverse
mechanisms such as endothelial dysfunction [30] or al-
tered hemostatic factors (higher levels of fibrinogen [31],
plasminogen activator-inhibitor-1 [32,33] or VonWille-
brand factor [34]), or altered platelet function [35–38]).
Molecular mechanisms linking hyperglycemia and
atherosclerosis have been recently reviewed by Aronson et
al [39].
There are also data to suggest that DM may predispose to
HF development through the existence of a specific dia-Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/1
Page 6 of 16
(page number not for citation purposes)
Figure 4
Incidence of HF and myocardial infarction (MI) as a function of glycemic control in diabetic populations. The 
incidence of both HF (Fig 4A) and MI (Fig 4B) was positively correlated with HbA1c levels. Adapted from reference [22].
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betic cardiomyopathy [40]. The exact mechanism(s) by
which DM may induce HF independent of epicardial cor-
onary artery disease is (are) unknown but several hypoth-
eses have been advanced; these include microangiopathy,
metabolic factors, and fibrosis. Intramyocardial microan-
giopathy has also been observed in diabetic hearts [41–
43]; combined with functional abnormalities related to
endothelial dysfunction, diabetic microangiopathy may
explain the reduced coronary blood flow reserve observed
in diabetic patients [30,44,45]. Metabolic factors may also
play a role in the development of myocardial dysfunction;
hyperglycemia, impaired myocardial glucose uptake, and
increased turnover of free fatty acids may all contribute to
DM-related myocardial dysfunction (for review see [46–
48]. Finally, experimental and clinical data also point to a
potential role for myocardial fibrosis in diabetic cardio-
myopathy; intramyocardial accumulation of collagen is a
well-demonstrated consequence of DM [49,50]; moreo-
ver, the deposition of advanced glycation end products
(AGEs) may result in increased left ventricular stiffness
and consequently to diastolic dysfunction [51–53]. In
summary, various mechanisms may induce a specific dia-
betic cardiomyopathy. Whether this diabetic cardiomyop-
athy alone may cause HF is however unknown; another
possibility is that these myocardial alterations related to
DM may predispose to the development of HF in response
to other insults such as coronary artery disease or hyper-
tension (Figure 6). After an acute myocardial infarction,
Figure 5
Incidence of MI in diabetic versus nondiabetic populations. The 7-year incidence of MI is much higher in diabetics than 
in nondiabetics. This holds true for patients with or without prior MI. The risk of MI in diabetics without prior MI is similar to 
that observed in nondiabetics with prior MI. Adapted from reference [29].
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decreased compensatory responses of non-infarcted area
have been described in diabetic patients [54–56]. Similar-
ly, a synergistic effect may exist between DM and hyper-
tension for the development of myocardial fibrosis [57].
Determining diabetic status: an additional prognostic indi-
cator in heart failure patients?
Risk stratification is an important step in the management
of patients with HF; high risk patients may indeed benefit
from more aggressive therapeutic strategies. Parameters
such as New York Heart Association (NHYA) class, maxi-
mal VO2, left and right ventricular ejection fraction have
been identified as powerful predictors of clinical outcome
in HF patients [58–62].
The first suggestion that DM may be a predictor of poor
clinical outcome in HF patients came in a report from
Shindler et al [17]. A subgroup analysis of the SOLVD tri-
als (combining the Prevention and the Treatment trials),
showed that both all cause mortality and cardiovascular
mortality at a mean follow-up of 3 years were significantly
higher in diabetic patients than in non-diabetic patients
(Figure 7). Multivariate analysis was used to assess the sig-
nificance of DM as an independent predictor of outcome.
Figure 6
Potential mechanisms linking diabetes mellitus to heart failure. Diabetes mellitus is associated with multiple physio-
pathological changes in the cardiovascular system. Among these, endothelial dysfunction and hemostatic disorders may at least 
in part account for the higher risk of coronary artery disease (CAD) while microangiopathy, myocardial fibrosis, and abnormal 
myocardial metabolism have been implicated in the pathogenesis of a specific diabetic cardiomyopathy. When it occurs in dia-
betic patients, heart failure (HF) is, in most cases, a consequence of CAD; other possible causes include the comorbidities fre-
quently encountered in diabetic patients such as hypertension, or other causes of nonischemic cardiomyopathy. The existence 
of a diabetic cardiomyopathy may increase the risk of HF in response to these insults; however, whether diabetic cardiomyop-
athy alone may be responsible for HF remains unknown.
Diabetic
Cardiomyopathy
Heart Failure
CAD
+
Other 
Nonischemic
Causes of HF
(Toxic, Viral, …)
Comorbidities
(Hypertension, …)
+
+
Diabetes
Micro-
angiopathy
Myocardial
fibrosis
Abnormal
metabolism
Hemostatic
disorders
Endothelial
dysfunctionCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/1
Page 9 of 16
(page number not for citation purposes)
After adjusting for important baseline variables such as
age, sex, NYHA classification, or left ventricular ejection
fraction, DM remained a significant predictor of clinical
outcome in both the Prevention and the Treatment trials.
More recently, Dries et al reanalyzed the SOLVD database
to determine whether DM would have a different impact
on clinical outcome in ischemic versus non-ischemic HF
[27]. After adjustment for baseline variables, they found
that DM was associated with an increased risk for all-cause
mortality in patients with ischemic HF (RR 1.37, 95% CI
1.21 to 1.55), but not in patients with non-ischemic HF
(RR 0.98, 95% CI 0.76 to 1.32) (Figure 8). Moreover, they
suggested that the increased mortality in patients with
ischemic HF compared with non-ischemic HF (reviewed
in [63]) may be limited to the diabetic subgroup. If these
findings are confirmed in independent studies, at least
two explanations may account for the negative interaction
between DM and the ischemic etiology of heart failure.
Firstly, diabetic HF patients may have a higher risk of cor-
onary plaque rupture and thrombosis [29,64]; recurrent
myocardial infarction is a major cause of death in patients
with ischemic HF [65]; in addition, non fatal myocardial
infarction may further deteriorate left ventricular function
in patients with ischemic HF. Furthermore, the presence
of various components of a specific diabetic cardiomyop-
athy such as impaired myocardial glucose uptake may be
especially deleterious in patients with ischemic HF [66–
69].
The links between DM and HF: the need for new studies
Most of the data on HF in diabetics summarized above
have been obtained from post-hoc analysis of rand-
omized studies or registries and as such should be inter-
preted with caution. In the SOLVD trial for example, the
Figure 7
Diabetes mellitus as a predictor of clinical outcome in HF populations. All cause mortality and cardiovascular mortal-
ity are higher in diabetics than in nondiabetics. Adapted from the SOLVD trials [17].
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diagnosis of DM was solely based on self-reporting by the
patient or on documentation in the patient's medical
records and data on the duration of DM, severity of DM,
and medications used to treat DM were not available.
Similarly, in SOLVD, the definition of the etiology of HF
(i.e., ischemic versus non ischemic) was based on the
judgement of the investigators at the participating sites af-
ter reviewing all available information and did not rou-
tinely include cardiac catheterization or non-invasive
testing.
New studies in HF populations with careful and prospec-
tive characterization of diabetic patients are needed; these
studies may be designed either as ancillary studies of pro-
spective randomized trials or as part of prospective regis-
tries on HF. The variables recorded should provide
information on DM type and duration, and antidiabetic
management (diet alone, oral hypoglycemic drugs, insu-
lin). The presence/absence of signs of end-organ damage
(retinopathy, neuropathy, nephropathy) would be a use-
ful indicator of DM severity and duration and should also
be recorded. Important biological variables related to the
presence of DM or its complications (glycemia, HbA1c,
serum creatinine, albuminuria, etc.) should also be pro-
spectively determined. Finally, in view of the potential in-
teractions between DM and CAD on HF risk and outcome,
special attention should be given to prospective character-
Figure 8
Prognostic impact of diabetes mellitus according to HF etiology. Subgroup analysis of the SOLVD trials. The deleteri-
ous impact of diabetes mellitus is limited to the ischemic subgroup. Adapted from reference [27].
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ization of HF etiology (i.e., ischemic versus non ischem-
ic).
Such studies would provide information on the character-
istics of the diabetic cohort in HF populations and on the
relationship between CAD and HF in diabetics. In addi-
tion, when coupled with clinical follow-up, these studies
would allow propective confirmation of the hypothesis
that DM has a deleterious impact on prognosis in HF pa-
tients and could determine whether biological markers
such as HbA1c may serve as prognostic indicators in HF
patients.
Treatment of HF in diabetic patients
Medical treatment
Post-hoc analyses of large randomized studies have
shown that the beneficial effect of conventional HF treat-
ment is maintained in the subgroup of diabetic patients.
This has been conclusively demonstrated for the two class-
es of drugs, regarded as cornerstone treatments, namely
ACE inhibitors and beta-blockers. In the SOLVD preven-
tion and Treatment trials [70,71], patients were rand-
omized to either placebo or the ACE inhibitor enalapril;
the efficacy was similar in diabetic and non-diabetic pa-
tients (Figure 7). There was no interaction between diabet-
ic status and drug assignement with respect to the study
endpoints [17]. In the ATLAS trial [4], patients were rand-
omized to high or low doses lisinopril. The relative risk re-
duction in mortality for high-dose vs low-dose lisinopril
was 14% for patients with diabetes mellitus and 6% for
those without [18]; high-dose lisinopril was as effective in
reducing hospitalizations for heart failure in diabetics as
in non-diabetics (21% vs 24%) [18]. In ACE inhibitor-in-
tolerant HF patients, the available literature supports the
use of angiotensin II blockers [72]. In the CIBIS II trial, pa-
tients were randomized to placebo or the beta-blocker
bisoprolol [3]; the efficacy was similar in diabetic and
non-diabetic patients with respect to all mortality/mor-
bidity endpoints [73]. For example, the relative risk (biso-
prolol vs placebo) for mortality was 0.81 (95% CI 0.51–
1.28) in diabetics and 0.66 (95% CI 0.54–0.81) in non-
diabetics; the heterogeneity test for interaction was not
statistically significant. Although these results were ob-
tained from post-hoc analyses and as such have limita-
tions from a methodological standpoint, the well-
demonstrated benefits of ACE inhibitors and beta-block-
ers appears to be maintained in the diabetic subgroups. In
addition, a similar relative risk reduction when applied to
a high risk population such as diabetic HF patients will
automatically translate into a major benefit in term of re-
duction in the absolute number of events.
In addition to ACE inhibitors and beta-blockers, patients
with ischemic HF also benefit from secondary prevention
with agents demonstrated to reduce atherosclerosis pro-
gression and to diminish the rate of acute coronary events.
The use of antiplatelet agents was associated with an im-
provement in survival in patients with symptomatic or
asymptomatic left ventricular dysfunction in the SOLVD
study [74]. Statin therapy has been associated with an im-
proved outcome in patients with coronary artery disease
and left ventricular dysfunction [75]; moreover, in the 4S
study, administration of simvastatin reduced the occur-
rence of HF [76]. Although no data are available concern-
ing diabetic patients with ischemic HF, the demonstrated
benefit of antiplatelet and statin therapy in diabetic pa-
tients with coronary artery disease [77–79] clearly sup-
ports a strategy of aggressive secondary prevention in
diabetic patients with ischemic HF.
The need for new strategies/studies
Besides medical treatment for HF and the optimal use of
secondary prevention strategies in cases with an ischemic
origin, there are still important unanswered questions
that will require further studies. For many diabetic pa-
tients with ischemic HF, the decision to revascularize and
the choice of the revascularization technique are key is-
sues. Moreover, the impact of DM treatment on HF out-
come also needs to be considered.
Myocardial revascularization
Patients with ischemic cardiomyopathy represent an im-
portant subset of HF patients in whom myocardial revas-
cularization may offer the potential for reduced
symptoms and enhanced prognosis [80–84]. The optimal
therapeutic strategy for coronary revascularization of dia-
betic patients is still a matter of debate [85–90]. Limited
data are available regarding the relative merits of Coro-
nary Artery Bypass Grafting (CABG) versus Percutaneous
Transluminal Coronary Angioplasty (PTCA) in diabetic
patients with ischemic HF: in a recent report of the Bypass
Angioplasty Revascularization Investigation (BARI) study,
the 7-year mortality was compared in patients rand-
omized to CABG or PTCA according to the presence or ab-
sence of diabetes mellitus and left ventricular dysfunction
at baseline [90]. In non-diabetic patients with left ven-
tricular dysfunction the 7-year survival was similar in the
CABG group and the PTCA group; on the other hand, in
diabetic patients with left ventricular dysfunction CABG
was associated with a better outcome than PTCA (Figure
9). Although these results support the choice of CABG as
revascularization technique for diabetic patients with left
ventricular dysfunction and multivessel coronary artery
disease, it must be noted that patient selection and inclu-
sion in the BARI study was performed >10 years ago [85].
Since then, new modalities of myocardial revasculariza-
tion have been developed; the generalisation of the use of
arterial grafts [85] and of coronary stent implantation
[91,92], and the advent of IIb/IIIa antagonists [93,94] all
have the potential to improve the outcome of diabetic HFCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/1
Page 12 of 16
(page number not for citation purposes)
patients undergoing myocardial revascularization. Simi-
larly, the recent demonstration that drug eluting stents
may significantly reduce the risk of restenosis could have
a major impact in diabetic HF patients undergoing percu-
taneous coronary revascularization [95].
Future studies will have to clarify the role of revasculariza-
tion in diabetic patients with ischemic HF. It will be im-
portant to determine if revascularization in diabetics
carries any advantage over medical therapy, a question
that is currently under evaluation in the BARI 2D study
(although not specifically in HF patients). If it is shown
that revascularization improves prognosis, it would be ap-
propriate to aggressively exclude an ischemic origin in di-
abetic HF patients.
Metabolic control
The impact of DM treatment in HF patients should also be
considered. At the present time, it has not been deter-
mined whether improved metabolic control might favora-
bly influence the outcome of diabetic HF patients and
large clinical studies are urgently needed to provide an an-
swer to this important question. The need for such studies
is underlined by preliminary data suggesting that strict
metabolic control may reverse to some extent the conse-
quence of diabetic cardiomyopathy [96]. Such studies
Figure 9
Survival in patients with multivessel CAD treated by CABG or PTCA according to presence/absence of diabe-
tes mellitus and left ventricular dysfunction at baseline. Adapted from the BARI study [90]. In the diabetes mellitus 
(DM) subgroup, the outcome was better in the CABG group than in the PTCA group; this holds true in the presence or in the 
absence of left ventricular dysfunction.
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would also determine whether the preferred treatment for
DM should be an insulin-sensitizing regimen or an insu-
lin-providing regimen. Lifestyle interventions [97] (in-
cluding dietary changes, increased physical activity and
weigth loss) could also be specifically tested in diabetic
HF patients. Finally, taking into account the possible in-
teraction between HF etiology and the impact of metabol-
ic control, prespecified subgroup analysis (non ischemic
HF vs ischemic HF) would appear mandatory.
Conclusions
In summary, HF in diabetic patients is an important
health problem. Approximately 20 to 25% of HF patients
are diabetics. The review of the available literature sug-
gests that the diabetic subgroup of HF patients deserves
special consideration: at the present time, the natural his-
tory of HF in diabetic patients appears different with a
higher mortality especially in the case of ischemic HF;
moreover, although conventional HF treatments appear
to be uniformly beneficial, in the case of ischemic HF the
choice of the revascularization technique may differ ac-
cording to diabetic status. Thus, an early and precise char-
acterization of diabetic status should be encouraged not
only in future clinical trials but also in everyday manage-
ment of HF patients.
The present review underscores the need for new studies
to help unravel the interplay between diabetes, atheroscle-
rosis, and heart failure and to determine the specific role
of currently available and novel therapies in the diabetic
population.
Finally, a better understanding of the mechanisms leading
to HF in diabetic patients may also help to design preven-
tive strategies. At the present time, the well-documented
beneficial effects of primary prevention of CAD in diabet-
ics supports the preventive use of drugs such as statins
[98] and ACE inhibitors [99]; other aspects such as for ex-
ample careful blood pressure control [100] may also have
a tremendous impact on the prevention of HF in this high
risk population.
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